title: [Expression of phosphatase and tensin homolog in lower rectal cancer on neoadjuvant chemoradiotherapy].
abstract: OBJECTIVE
  To explore the expression of phosphatase and tensin homolog deleted on chromosome ten (PTEN) in low rectal cancer on neoadjuvant chemoradiotherapy with capecitabine plus radiotherapy.
  
  
  METHODS
  Sixty-six patients with low rectal cancer on therapy with capecitabine (1650 mg×m(-2)×d(-1) in 2 divided doses) for two course and concurrent radiotherapy (50 Gy, 2 Gy/day, 5 days a week). Then the investigators analyzed the relationship between the preoperative neoadjuvant chemoradiotherapy and prognosis and measured the expression of PTEN during neoadjuvant chemoradiotherapy.
  
  
  RESULTS
  92.4% (61/66) of patients received neoadjuvant chemoradiotherapy as planned. 87.9% (58/66) tumor stages were down-staged, tumor size decreased while the distance from anal edge increased. And curative resection with sphincter-sparing was carried out in all patients. The rate of sphincter preservation was 90.9% (60/66). Among which, 85.5% patients showed an excellent function of sphincter. The 2-year survival rate was 87.9% (58/66). The survival period was an average of 35.3 months (range: 25-60). The PTEN mRNA and protein expression in cancer tissues on neoadjuvant chemoradiotherapy were significantly higher than those before neoadjuvant chemoradiotherapy (P=0.0079, 0.0269).
  
  
  CONCLUSIONS
  The preoperative neoadjuvant chemoradiotherapy in lower rectal cancer patients has shown its efficacy in down-staging cancer, enhancing resectability, offering sphincter preservation, up-regulating PTEN expression, promoting the apoptosis of cancer cell and achieving a better survival rate. Thus preoperative neoadjuvant chemoradiotherapy is an effective adjuvant measure.
authors.affiliation: Department of Oncology, Affiliated Wujin People's Hospital, Jiangsu University, Changzhou 213002, China. jjh20102010@163.com
authors.forename: Jian-hua
authors.initials: JH
authors.lastname: Jin
authors.forename: Ya-xiong
authors.initials: YX
authors.lastname: Rong
authors.forename: Fang
authors.initials: F
authors.lastname: Wang
authors.forename: Xi-yuan
authors.initials: XY
authors.lastname: Xu
authors.forename: Wen-bin
authors.initials: WB
authors.lastname: Lu
authors.forename: Xian-wen
authors.initials: XW
authors.lastname: Li
authors.forename: Jian-zhong
authors.initials: JZ
authors.lastname: Deng
authors.forename: Hua
authors.initials: H
authors.lastname: Zhang
authors.forename: Xue-zhong
authors.initials: XZ
authors.lastname: Xu
authors.forename: Zhi-xin
authors.initials: ZX
authors.lastname: Xue
mesh_terms: D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000532:radiotherapy
chemical_list: D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human